Immunotherapy and EGFR, ALK Inhibitors Deliver Precision Medicine in NSCLC – OncLive
OncLive |
Immunotherapy and EGFR, ALK Inhibitors Deliver Precision Medicine in NSCLC
OncLive Here, alectinib improved PFS versus standard crizotinib (Xalkori) by 47% (HR, 0.53; 95% CI, 0.38-0.73; P <.0001).2 Immunotherapy has not gone unnoticed either, with the May 2017 approval of pembrolizumab (Keytruda) in combination with carboplatin … |
